Vertex and NHS England Set Date For Next Round Of Orkambi Pricing Talks
Vertex and NHS England are to resume talks next week over pricing of cystic fibrosis drug Orkambi.
You may also be interested in...
Vertex and NHS England are under pressure to strike a deal on cystic fibrosis drug Orkambi after UK a parliamentary debate put health technology appraisal body NICE under the spotlight.
Despite an initial rejection from NHS England, Vertex remains committed to bringing its novel reimbursement plan to England to secure access to its cystic fibrosis drug, Orkambi.
The difficulties in getting advanced therapies, such as Novartis’ CAR T therapy Kymriah, to patients have shifted and manufacturing capacity is no longer the biggest issue.